z-logo
open-access-imgOpen Access
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
Author(s) -
Ahmed O. Kaseb,
S Cheenu Kappadath,
Sunyoung S. Lee,
Kanwal Raghav,
Yehia I. Mohamed,
Lianchun Xiao,
Jeffrey S. Morris,
Chimela Ohaji,
Rony Avritscher,
Bruno C. Odisio,
J. Kuban,
Mohamed E. Abdelsalam,
Beth Chasen,
Khaled M. Elsayes,
Mohamed Elbanan,
Robert A. Wolff,
James C. Yao,
Armeen Mahvash
Publication year - 2021
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s318865
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , gastroenterology , adverse effect , vomiting , nausea , prospective cohort study , surgery
The most common cause of death in advanced/metastatic hepatocellular carcinoma (HCC) is liver failure due to tumor progression. While retrospective studies and meta-analyses of systemic therapy combined with liver-directed therapy have been performed, prospective studies of safety/efficacy of antiangiogenesis followed by intra-arterial therapies are lacking. We tested our hypothesis that sorafenib followed by yttrium 90 glass microspheres ( 90 Y GMs) is safe and that survival outcomes may improve by controlling hepatic tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here